All patients
Age < 65y (younger) Age > 65y cancer type (metastatic) cancer type (recurrent) ECOG 0 ECOG 1 Gender, female Gender, male P16 negative (HPV) P16 positive (HPV) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mHNSCC - L1 - PDL1 positive, pembrolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.78 [0.64; 0.96]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.61 [0.45; 0.83]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.63 [0.51; 0.77]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.60 [0.44; 0.81]
0.67 [0.59 ; 0.76 ] KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 4 11% 1,471 moderate not evaluable deaths (OS) (extension)detailed results KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.74 [0.61; 0.90]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.58 [0.44; 0.77]
0.67 [0.53 ; 0.85 ] KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019 2 47% 767 moderate not evaluable progression or deaths (PFS)detailed results KEYNOTE-048 (P vs C ; CPS > 1), 2019 1.16 [0.96; 1.40]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.99 [0.75; 1.30]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.82 [0.67; 1.00]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.73 [0.55; 0.97]
0.92 [0.75 ; 1.13 ] KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 4 70% 1,471 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.44 [0.29; 0.66]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.11 [0.06; 0.20]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 1.03 [0.71; 1.49]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 1.21 [0.72; 2.05]
0.50 [0.20 ; 1.29 ] KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 4 94% 1,480 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-01 12:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 109
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561
